Porf-2 Inhibits Tumor Cell Migration Through the MMP-2/9 Signaling Pathway in Neuroblastoma and Glioma

Frontiers in Oncology
Xue-Yuan LiDong-Ming Yan

Abstract

Tumor migration and invasion are key pathological processes that contribute to cell metastasis as well as treatment failure in patients with malignant tumors. However, the mechanisms governing tumor cell migration remain poorly understood. By analyzing the tumor-related database and tumor cell lines, we found that preoptic regulatory factor-2 (Porf-2) is downexpressed in both neuroblastoma and glioma. Using in vitro assays, our data demonstrated that the expression of Porf-2 inhibits tumor cell migration both in neuroblastoma and glioma cell lines. Domain-mutated Porf-2 plasmids were then constructed, and it was found that the GAP domain, which plays a role in the inactivation of Rac1, is the functional domain for inhibiting tumor cell migration. Furthermore, by screening potential downstream effectors, we found that Porf-2 can reduce MMP-2 and MMP-9 expression. Overexpression of MMP-2 blocked the inhibitory effect of Porf-2 in tumor cell migration both in vitro and in vivo. Taken together, we show for the first time that Porf-2 is capable of suppressing tumor cell migration via its GAP domain and the downregulation of MMP-2/9, suggesting that targeting Porf-2 could be a promising therapeutic strategy for nervous system tumors.

References

Sep 3, 2004·Genes & Development·Annika LundströmChristos Samakovlis
Mar 10, 2005·Proceedings of the National Academy of Sciences of the United States of America·Hailan HuGreg J Bashaw
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger StuppArnab Chakravarti
Feb 6, 2008·Journal of Neuro-oncology·G MinnitiR Maurizi Enrici
Oct 24, 2008·The New England Journal of Medicine·Michael A Meyer
Mar 10, 2010·Archives of Neurology·Jennifer ClarkeSusan Chang
Jun 19, 2010·The New England Journal of Medicine·John M Maris
Sep 9, 2010·Cell Communication and Signaling : CCS·Matteo Parri, Paola Chiarugi
Jan 27, 2011·PLoS Biology·Graciana Diez-RouxAndrea Ballabio
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 12, 2011·Cell Cycle·Natalie A MackAngeliki Malliri
Nov 30, 2011·Journal of Cell Science·Michael L Kerber, Richard E Cheney
Jun 30, 2015·Expert Review of Neurotherapeutics·Shivani MittalTapasya Srivastava
Apr 12, 2016·Frontiers in Cellular Neuroscience·Guo-Hui HuangDong-Fu Feng
Feb 7, 2017·Molecular and Cellular Neurosciences·Guo-Hui HuangDong-Fu Feng
Apr 4, 2017·Scientific Reports·Jin-Yu LeeMau-Sun Chang
Jun 20, 2017·Frontiers in Molecular Neuroscience·Xi-Tao YangDong-Fu Feng
Sep 16, 2017·Pharmacology & Therapeutics·Sepp JansenMartina Schmidt
Jun 26, 2018·Cellular and Molecular Life Sciences : CMLS·Guo-Hui HuangDong-Fu Feng
Feb 15, 2019·Frontiers in Pharmacology·Vincenzo CarafaAngela Nebbioso
Apr 14, 2019·Gene·Murali Dharan BashyamSara Anisa George
May 6, 2019·Cancer Research·Danny R Welch, Douglas R Hurst
Jul 28, 2019·Journal of Clinical Medicine·Tatiana S GerashchenkoVladimir M Perelmuter

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
GTPase
transfection
pull down
electrophoresis
Xenografts
fluorescence
PCR
pull-down
GTPases

Related Concepts